Bnp Paribas Asset Management Holding S.A. Travere Therapeutics, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 684 shares of TVTX stock, worth $20,280. This represents 0.0% of its overall portfolio holdings.
Number of Shares
684Holding current value
$20,280% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
235Shares Held
103MCall Options Held
1.71MPut Options Held
401K-
Janus Henderson Group PLC London, X09.54MShares$283 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY8.88MShares$263 Million2.3% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$227 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$178 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$151 Million0.1% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.9B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...